Séverine Crettol Wavre

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


46 publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
 
Genetic and clinic predictors of new onset diabetes mellitus after transplantation.
Saigi-Morgui N., Quteineh L., Bochud P.Y., Crettol S., Kutalik Z., Mueller N.J., Binet I., Van Delden C., Steiger J., Mohacsi P. et al., 2019/02. The pharmacogenomics journal, 19 (1) pp. 53-64. Peer-reviewed.
 
Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4.
Ghassabian S., Gillani T.B., Rawling T., Crettol S., Nair P.C., Murray M., 2019/01/09. The AAPS journal, 21 (2) p. 15. Peer-reviewed.
Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients.
Quteineh L., Wójtowicz A., Bochud P.Y., Crettol S., Vandenberghe F., Venetz J.P., Manuel O., Golshayan D., Lehmann R., Mueller N.J. et al., 2019/01. American journal of transplantation, 19 (1) pp. 238-246. Peer-reviewed.
Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances
Delacrétaz Aurélie, Vandenberghe Frederik, Glatard Anaïs, Levier Axel, Dubath Céline, Ansermot Nicolas, Crettol Séverine, Gholam-Rezaee Mehdi, Guessous Idris, Bochud Murielle et al., 2018/11/09. Frontiers in Psychiatry, 9.
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation.
Quteineh L., Bochud P.Y., Golshayan D., Crettol S., Venetz J.P., Manuel O., Kutalik Z., Treyer A., Lehmann R., Mueller N.J. et al., 2017/01. The pharmacogenomics journal, 17 (1) pp. 69-75. Peer-reviewed.
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.
Csajka C., Crettol S., Guidi M., Eap C.B., 2016/12. Clinical pharmacokinetics, 55 (12) pp. 1521-1533. Peer-reviewed.
Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers.
Vandenberghe F., Saigí-Morgui N., Delacrétaz A., Quteineh L., Crettol S., Ansermot N., Gholam-Rezaee M., von Gunten A., Conus P., Eap C.B., 2016/12. Pharmacogenetics and genomics, 26 (12) pp. 547-557. Peer-reviewed.
 
Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts.
Marie-Claire C., Crettol S., Cagnard N., Bloch V., Mouly S., Laplanche J.L., Bellivier F., Lepine J.P., Eap C., Vorspan F., 2016/02. Epigenomics, 8 (2) pp. 181-195. Peer-reviewed.
Eine unerwünschte Wirkung von Methadon und Moxifloxacin
Liakoni E., Huber X., Stegert M., Crettol S., Eap CB., Liechti ME., 2016. Schweizerisches Medizin-Forum, 16 pp. 176-177. Peer-reviewed.
Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations.
Saigi-Morgui N., Quteineh L., Bochud P.Y., Crettol S., Kutalik Z., Wojtowicz A., Bibert S., Beckmann S., Mueller N.J., Binet I. et al., 2016. PloS one, 11 (10) pp. e0164443. Peer-reviewed.
 
The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens.
Sakae D.Y., Marti F., Lecca S., Vorspan F., Martín-García E., Morel L.J., Henrion A., Gutiérrez-Cuesta J., Besnard A., Heck N. et al., 2015. Molecular Psychiatry, 20 (11) pp. 1448-1459. Peer-reviewed.
Can Valproic Acid be an Inducer of Clozapine Metabolism?
Diaz F.J., Eap C.B., Ansermot N., Crettol S., Spina E., de Leon J., 2014. Pharmacopsychiatry, 47 (3) pp. 89-96. Peer-reviewed.
 
Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.
Crettol S., de Leon J., Hiemke C., Eap C.B., 2014. Clinical Pharmacology and Therapeutics, 95 (3) pp. 254-257. Peer-reviewed.
 
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M., Crettol S., Oneda B., Lahyani R., Rotger M., Choong E., Lubomirov R., Csajka C., Eap C.B., 2013. Pharmacogenetics and Genomics, 23 (2) pp. 84-93. Peer-reviewed.
 
Cytochrom-P450-Genotypisierung: ein Instrument zur Personalisierung der medikamentösenBehandlung in der Psychiatrie
Crettol Séverine, Eap Chin Bin, 2013. Pipette : Swiss Laboratory Medicine 6 pp. 10-11.
 
Cytochromes P450: génotypage et /ou phénotypage pour l'individualisation du traitement médicamenteux
Crettol Séverine, Eap Chin B., 2013. Pipette 1 pp. 10-11.
 
Adherence to antidepressant treatment: what the doctor thinks and what the patient says.
Loayza N., Crettol S., Riquier F., Eap C.B., 2012. Pharmacopsychiatry, 45 (5) pp. 204-207. Peer-reviewed.
 
Clinical effectiveness, pharmacokinetics and pharmacogenetics of mirtazapine in depression
Jaquenoud Sirot E., Harenberg S., Vandel P., Mendonça Lima C.A., Perrenoud P., Kemmerling K., Zullino D.F., Hilleret H., Crettol S., Jonzier-Perey M. et al., 2012. pp. 45 - A10 dans Psychotropic Drugs: Risks and Risk Management : Xth Congress of the Interdisciplinary TDM Task Force of the AGNP together with the Swiss Society for Pharmacovigilance in Psychiatry (SGAMSP) and the Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP), Pharmacopsychiatry. Peer-reviewed.
 
Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression.
Jaquenoud Sirot E., Harenberg S., Vandel P., Lima C.A., Perrenoud P., Kemmerling K., Zullino D.F., Hilleret H., Crettol S., Jonzier-Perey M. et al., 2012. Journal of Clinical Psychopharmacology, 32 (5) pp. 622-629. Peer-reviewed.
 
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
Oneda B., Crettol S., Bochud M., Besson J., Croquette-Krokar M., Hämmig R., Monnat M., Preisig M., Eap C.B., 2011. Pharmacogenomics Journal, 11 (4) pp. 258-266. Peer-reviewed.
 
Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.
Nebot N., Crettol S., d'Esposito F., Tattam B., Hibbs D.E., Murray M., 2010/11. British journal of pharmacology, 161 (5) pp. 1059-1069. Peer-reviewed.
 
Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval.
Ansermot N., Albayrak O., Schläpfer J., Crettol S., Croquette-Krokar M., Bourquin M., Déglon J.J., Faouzi M., Scherbaum N., Eap C.B., 2010/03/22. Archives of internal medicine, 170 (6) pp. 529-536. Peer-reviewed.
 
Evidence-based medicine for pharmacogenetics
Rossier Michel F., Rebsamen Michaela, Crettol Severine, Eap Chin B., Rentsch Katharina, 2010. Pipette : Swiss Loboratory Medicine 4 pp. 13-15.
 
Pharmacogenetics of phase I and phase II drug metabolism.
Crettol S., Petrovic N., Murray M., 2010. Current pharmaceutical design, 16 (2) pp. 204-219. Peer-reviewed.
 
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B., Crettol S., Jaquenoud Sirot E., Bochud M., Ansermot N., Eap C.B., 2009/11. Pharmacogenetics and genomics, 19 (11) pp. 877-883. Peer-reviewed.
 
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E., Knezevic B., Morena G.P., Harenberg S., Oneda B., Crettol S., Ansermot N., Baumann P., Eap C.B., 2009. Journal of clinical psychopharmacology, 29 (4) pp. 319-26. Peer-reviewed.
Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study.
Hallinan R., Crettol S., Agho K., Attia J., Besson J., Croquette-Krokar M., Hämmig R., Déglon J.J., Byrne A., Ray J. et al., 2009. European Journal of Clinical Pharmacology, 65 (11) pp. 1113-1120.
 
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.
Crettol S., Besson J., Croquette-Krokar M., Hämmig R., Gothuey I., Monnat M., Déglon J.J., Preisig M., Eap C.B., 2008. Progress in Neuro-psychopharmacology and Biological Psychiatry, 32 (7) pp. 1722-1727. Peer-reviewed.
 
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S., Venetz J.P., Fontana M., Aubert J.D., Pascual M., Eap C.B., 2008. Therapeutic Drug Monitoring, 30 (6) pp. 689-699. Peer-reviewed.
 
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients
Crettol Séverine, Venetz Jean-Pierre, Fontana Massimiliano, Aubert John-David, Ansermot Nicolas, Fathi Marc, Pascual Manuel, Eap Chin-Bin, 2008. Pharmacogenetics and Genomics, 18 (4) pp. 307-315. Peer-reviewed.
 
No influence of ABCB1 haplotypes on methadone dosage requirement
Crettol Séverine, Déglon Jean-Jacques, Besson Jacques, Croquette-Krokar Marina, Hämmig Robert, Gothuey Isabelle, Monnat Martine, Eap Chin-Bin, 2008. Clinical Pharmacology and Therapeutics, 83 (5) pp. 668-669. Peer-reviewed.
 
Response to "methadone-induced QTc prolongation: is it due to stereoselective block of hERG or to inappropriate QT interval correction?"
Crettol Séverine, Schlaepfer Jürg, Abriel Hugues, Eap Chin-Bin, 2008. Clinical Pharmacology and Therapeutics, 83 (5) p. 672. Peer-reviewed.
 
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizer: evidence of a safer cardiac profile of (R)-methadone
Eap Chin Bin, Crettol Séverine, Rougier Jean-Sébastien, Schläpfer Jürg, Sintra Grilo Liliana, Déglon Jean-Jacques, Besson Jacques, Croquette-Krokar Marina, Carrupt Pierre-Alain, Abriel Hugues, 2008. pp. A6 dans 5th Regensburg Symposium on Clinical Pharmacology, Pharmacopsychiatry. Peer-reviewed.
Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression?
Crettol S., Monnat M., Eap C.B., 2007. Critical Care, 11 (1) p. 119. Peer-reviewed.
 
In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites
Crettol Séverine, Digon Patricia, Powell Golay Kerry, Brawand Marlyse, Eap Chin-Bin, 2007. Pharmacology, 80 (4) pp. 304-311. Peer-reviewed.
 
Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients
Uehlinger Claude, Crettol Séverine, Chassot Philippe, Brocard Murielle, Koeb Liliane, Brawand-Amey Marlyse, Eap Chin-Bin, 2007. Journal of Clinical Psychopharmacology, 27 (3) pp. 273-278. Peer-reviewed.
 
Pharmacokinetic and pharmacogenetic factors influencing methadone plasma levels
Crettol Séverine, Eap Chin-Bin, 2007. Heroin Addiction and Related Clinical Problems, 9 (2) pp. 39-46. Peer-reviewed.
 
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers.
Eap C.B., Crettol S., Rougier J.S., Schläpfer J., Sintra Grilo L., Déglon J.J., Besson J., Croquette-Krokar M., Carrupt P.A., Abriel H., 2007. Clinical Pharmacology and Therapeutics, 81 (5) pp. 719-728. Peer-reviewed.
 
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S., Déglon J.J., Besson J., Croquette-Krokar M., Hämmig R., Gothuey I., Monnat M., Eap C.B., 2006. Clinical pharmacology and therapeutics, 80 (6) pp. 668-81. Peer-reviewed.
 
Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status.
Baumann P., Barbe R., Vabre-Bogdalova A., Garran E., Crettol S., Eap C.B., 2006. Journal of clinical psychopharmacology, 26 (6) pp. 679-81. Peer-reviewed.
 
Genetic polymorphisms of CYP3A genes affect cyclosporine a blood concentration and dose requirement in transplant recipients
Crettol Séverine, Venetz Jean-Pierre, Aubert John-David, Fontana Massimiliano, Brocard Murielle, Pascual Manuel, Eap Chin-Bin, 2006. p. 197 dans NA, Transplantation. Peer-reviewed.
 
Influence of MDR1 genetic polymorphisms on intralymphocyte concentrations of cyclosporine A in transplant recipients
Crettol Séverine, Venetz Jean-Pierre, Aubert John-David, Fontana Massimiliano, Ansermot Nicolas, Fathi Marc, Brocard Murielle, Pascual Manuel, Eap Chin-Bin, 2006. p. 197 dans NA, Transplantation. Peer-reviewed.
 
Pharmacogenomics of opioids
Crettol Séverine, Eap Chin-Bin, 2006. dans Pharmacogenomics and proteomics : enabling the practice of personalized medicine / ed. by Steven H.Y. Wong, Mark W. Linder, Roland Valdes. - Washington, DC : AAC Press, 2006. - P. 187-198. - ISBN 1594250464, NA.
 
Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients.
Bondolfi G., Morel F., Crettol S., Rachid F., Baumann P., Eap C.B., 2005. Therapeutic drug monitoring, 27 (4) pp. 539-43. Peer-reviewed.
 
Influence of CYP2B6 polymorphism on the steady-state plasma levels of the enantiomers of methadone
Crettol Séverine, Déglon Jean-Jacques, Besson Jacques, Croquette-Krokar Marina, Gottuey I., Haemming R., Monnat Martine, Haottemann H., Baumann Pierre, Eap Chin-Bin, 2005. p. 121 dans NA, Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
 
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S., Déglon J.J., Besson J., Croquette-Krokkar M., Gothuey I., Hämmig R., Monnat M., Hüttemann H., Baumann P., Eap C.B., 2005. Clinical pharmacology and therapeutics, 78 (6) pp. 593-604. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University